亚甲基四氢叶酸还原酶基因多态性与大肠癌患者辅助化疗疗效的相关性研究

发布时间：2018-03-20 04:39

  本文选题：亚甲基四氢叶酸还原酶　切入点：基因多态性　出处：《中国药学杂志》2017年18期 　论文类型：期刊论文

【摘要】：目的研究亚甲基四氢叶酸还原酶基因(MTHFR)C677T多态性与大肠癌术后患者接受卡培他滨联合奥沙利铂(XELOX)方案辅助化疗疗效的关系。方法对行大肠癌根治术后接受XELOX方案化疗的62例患者,采用竞争性等位基因特异性聚合酶链式反应(KASP)法检测MTHFR C677T基因多态性并分析其与预后及不良反应相关性。结果 62例结直肠癌患者的MTHFR C677T位点存在3种等位基因型,其基因频率分别为:C/C 46.8%,C/T 40.3%,T/T 12.9%。C/T及T/T型患者无复发生存时间较C/C型延长(Log-rank=4.778,P0,05)。其中C/C型患者复发率为58.6%,显著高于T/T及C/T基因型患者的33.3%(χ~2=3.985,P0.05)。TNM分期(HR=5.326,P0,05)及MTHFR C677T基因多态性(HR=0.284,P0.05)是术后辅助化疗预后的影响因素。化疗毒副反应中以胃肠道反应和骨髓抑制为主,但不同基因型之间差异并不具有统计学意义(P0.05)。结论 MTHFR C677T基因多态性与XELOX方案辅助化疗预后相关。TNM分期(Ⅳ期)术后辅助化疗预后差。MTHFR C677T基因多态性与化疗引起的毒副反应无关。
[Abstract]:Objective to study the relationship between methylenetetrahydrofolate reductase gene MTHFRnC677T polymorphism and adjuvant chemotherapy efficacy of capecitabine combined with oxaliplatin XELOX regimen in patients with colorectal cancer. Methods 62 patients with colorectal cancer received XELOX regimen chemotherapy after radical resection of colorectal cancer. The polymorphism of MTHFR C677T gene was detected by competitive allele-specific polymerase chain reaction (KASP) method and its relationship with prognosis and adverse reactions was analyzed. Results there were three alleles at MTHFR C677T locus in 62 patients with colorectal cancer. The gene frequencies of C / C / C 46.8and T / T 40.30.3and T / T 12.9.Cr / T and T / T respectively prolong the recurrence survival time of patients with type C / C, and the recurrence rate of patients with C / C type is 58.60.It is significantly higher than that of patients with T / T and CT genotypes (蠂 ~ (33.3.985P0.05). TNM staging HR5.326P0O) and MTHFR C677T gene polymorphism HR0.284P0.05). The main adverse effects of adjuvant chemotherapy were gastrointestinal reaction and bone marrow suppression. Conclusion the polymorphism of MTHFR C677T gene is related to the prognosis of adjuvant chemotherapy of XELOX regimen. The prognosis of adjuvant chemotherapy is poor after the operation of stage 鈪，

本文编号：1637572